NVIGEN is a nanotechnology empowered personalized medicine innovator. Our pipeline of visionary solutions stems from our innovative nanomedicine platform. We are focusing on the development of a comprehensive circulating bio-marker biopsy technology, NVIGEN X™, to predict cancer recurrence at the earliest possible time and guide the most effective personalized therapy.
NVIGEN X™ is enabled by the state-of-the-art molecularly engineered nanoparticles, MagVigen™ and MyQuVigen™, to efficiently capture and identify molecular information from proteins, cells and nucleic acids. We are developing NVIGEN X™ into accurate, automated and FDA approved clinical instruments and reagent kits deployable at hundreds and thousands of hospitals, turning fatal cancers into manageable diseases.
Abcepta is a leading manufacturer of primary antibodies with more than fifteen years of experience. We supply quality antibodies and related products drug discovery and academic laboratories worldwide. Our focus is on targets covering the major research areas impacting health and disease, including cancer, metabolism, cardiovascular, neuroscience, and stem cells.
ABP Biosciences invents, develops, and markets innovative products and technologies to scientists engaged in life sciences research, diagnostic R&D and drug discovery. We specialize in the area of fluorescence labeling and detection technologies. Our products enable scientists and biomedical researchers to better understand molecular biology, cell biology, and immunology. We're committed to providing a wide array of high-quality, value-priced products.